Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or progression remains a significant challenge. In this study, we p...

Full description

Bibliographic Details
Main Authors: Wei Liu, Yan Xu, Yi Wang, Lugui Qiu, Ting Xie, Xiaojuan Wang, Huimin Liu, Tonghui Ma, Jianxiang Wang, Gang An, Weiwei Sui, Hesong Zou, Chunyang Wang, Chen Qiu, Dandan Shan, Wenyang Huang, Shuhua Yi, Dehui Zou
Format: Article
Language:English
Published: BMJ Publishing Group 2024-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/3/e008450.full

Internet

https://jitc.bmj.com/content/12/3/e008450.full

Similar Items